Imbria Pharmaceuticals Secures $57.5M Series B Financing for Cardiometabolic Therapies

Imbria Pharmaceuticals secures funding for novel cardiometabolic therapies with lead product showing promise in clinical trials.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here